Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06107062 · ClinicalTrials.gov registry record · Phase 2

Longitudinal Outpatient Treatment for Cannabis Use Disorder

A Phase 2 study of Cannabis Use Disorder, sponsored by University of Colorado, Boulder.

Recruiting
Registry status
Phase 2
Development phase
165
Enrollment target
1
Study location

NCT06107062 is a Phase 2 study of Cannabis Use Disorder that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 165 participants, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (59% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06107062, a Phase 2 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Boulder.

RECRUITING
Registry status
Phase 2
Development phase
165 participants
Enrollment target
1
Study location

Study Summary

This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy treatment for CUD. Blood is collected to quantify investigational drug exposure and cannabis use. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.

Conditions Studied

Cannabis Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol - fsCBD
  • DRUG Cannabidiol - bsCBD

Study Locations (1)

Colorado

  • University of Colorado Boulder - Boulder

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2024-05-16
Est. Completion 2029-03-31
Phase Phase 2

Sponsor

University of Colorado, Boulder

69 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06107062

The ClinicalTrials.gov registry entry for NCT06107062 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (59% higher). The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06107062 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT06107062 about?

NCT06107062 is a clinical study titled "Longitudinal Outpatient Treatment for Cannabis Use Disorder". This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate user...

What is the current status of trial NCT06107062?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2024-05-16. Estimated completion is 2029-03-31.

What conditions does trial NCT06107062 study?

This clinical trial studies the following conditions: Cannabis Use Disorder.

What interventions are being tested in trial NCT06107062?

The interventions under investigation include: Placebo (DRUG), Cannabidiol - fsCBD (DRUG), Cannabidiol - bsCBD (DRUG).

Who is sponsoring clinical trial NCT06107062?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06107062 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cannabis Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cannabis Use Disorder

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.